| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/25/2001 | EP1093465A2 Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| 04/25/2001 | EP1093383A1 Drug delivery system comprising a homeobox peptide |
| 04/25/2001 | EP1093361A1 Plaster which contains steroids, and a method for the production and use thereof |
| 04/25/2001 | EP1093348A1 Methods and transdermal compositions for pain relief |
| 04/25/2001 | EP0626863B1 Formulations containing hyaluronic acid |
| 04/25/2001 | CN1292816A Encapsulation of living tissue cells in microsphere |
| 04/25/2001 | CN1292707A Anhydrous topical skin preparation |
| 04/25/2001 | CN1292703A Bubbling enteric coated preparations |
| 04/25/2001 | CN1292692A Oral preparations containing forskolin derivatives and process for producing medicinal preparations |
| 04/25/2001 | CN1292691A Preparation for treatment of erectile dysfunction |
| 04/25/2001 | CN1292687A Nonoparticles, method for producing nanoparticles and use of the same |
| 04/25/2001 | CN1292684A Emulsion preconcentrate containing cyclosporin or macrolide |
| 04/25/2001 | CN1292683A Compositions containing organic compounds |
| 04/25/2001 | CN1064851C Microparticle, manufacture of same and application in diagnosis |
| 04/24/2001 | US6221979 Crosslinking |
| 04/24/2001 | US6221959 Polynucleotide, polymer complex |
| 04/24/2001 | US6221958 Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 04/24/2001 | US6221919 Utilization of ethoxylated fatty acid esters as self-emulsifiable compounds |
| 04/24/2001 | US6221917 Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| 04/24/2001 | US6221893 Administration of histamine for therapeutic purposes |
| 04/24/2001 | US6221853 Mixture of pharmaceutically acceptable purified paraffinic hydrocarbons, this vehicle having a melting point of about 37 degrees c.+-4 degrees c. |
| 04/24/2001 | US6221852 Pharmaceutical compositions of 5-alkynyl-dideoxyribouracil |
| 04/24/2001 | US6221403 Topical composition |
| 04/24/2001 | US6221400 Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors |
| 04/24/2001 | US6221396 Oral cisapride dosage forms with an extended duration |
| 04/24/2001 | US6221393 Used when it is desired to administer a medicament to a patient over a prolonged period without requiring the patient to take repeat doses at short intervals. |
| 04/24/2001 | US6221391 Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith |
| 04/24/2001 | US6221386 Therapeutic agent entrapped within a liposome comprising a smooth lipopolysaccharide from brucella melitensis. |
| 04/24/2001 | US6221385 Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof |
| 04/24/2001 | US6221383 Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| 04/24/2001 | US6221378 Mixed micellar delivery system and method of preparation |
| 04/24/2001 | US6221377 Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs |
| 04/24/2001 | US6221367 Exposing a biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex |
| 04/24/2001 | US6221365 NucA protein of Haemophilus influenzae |
| 04/24/2001 | US6221350 Enhancement of microbial colonisation of the gastrointestinal tract |
| 04/24/2001 | US6221346 Composition with base of coconut oil and its use |
| 04/24/2001 | US6221337 Microbubbles surrounded by a monolayer of negatively charged phospholipids as contrast agents |
| 04/24/2001 | CA2188703C Therapeutic injectable analgesic pharmaceutical composition containing nimesulide 4-nitro, 2-phenoxyphenyl methane sulphonamide for intramuscular administration |
| 04/24/2001 | CA2101164C Orally administerable drugs for the treatment of central dopamine deficiency conditions |
| 04/24/2001 | CA2030459C Biodegradable ocular implants |
| 04/24/2001 | CA2027630C Protein gel ophthalmic vehicle |
| 04/22/2001 | CA2324047A1 Photostabilization process for solar filters derived from dibenzoylmethane by a micronized insoluble organic filter |
| 04/19/2001 | WO2001027261A2 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 04/19/2001 | WO2001027154A2 Membrane translocating peptide drug delivery system |
| 04/19/2001 | WO2001027132A1 Estradiol conjugates and uses thereof |
| 04/19/2001 | WO2001027099A2 Bicyclic compounds composition and method for stabilizing the same |
| 04/19/2001 | WO2001026705A2 A dual adhesive transdermal drug delivery system |
| 04/19/2001 | WO2001026693A2 Manufacture of polyglutamate-therapeutic agent conjugates |
| 04/19/2001 | WO2001026692A1 Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation |
| 04/19/2001 | WO2001026691A1 Medicinal compositions for oral use |
| 04/19/2001 | WO2001026690A1 Percutaneous permeability-controlling agents and compositions for electroporation containing the same |
| 04/19/2001 | WO2001026689A1 Compositions for electroporation |
| 04/19/2001 | WO2001026688A1 Percutaneous absorption promoters for electroporation |
| 04/19/2001 | WO2001026683A2 Archaeosomes as adjuvants and carriers for acellular vaccines to induce cytotoxic t lymphocyte (ctl) responses |
| 04/19/2001 | WO2001026677A1 Interferon complex and medicinal use thereof |
| 04/19/2001 | WO2001026663A1 Extended release formulations of erythromycin derivatives |
| 04/19/2001 | WO2001026661A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 04/19/2001 | WO2001026649A1 Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| 04/19/2001 | WO2001026637A2 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 04/19/2001 | WO2001026636A1 Superficial therapeutic system for topically applying acetylsalicylic acid, for the treatment of acne-related diseases |
| 04/19/2001 | WO2001026635A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/19/2001 | WO2001026634A1 Tablets with a gellan gum coating |
| 04/19/2001 | WO2001026629A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 04/19/2001 | WO2001026628A1 Cationic dosper virosomes |
| 04/19/2001 | WO2001026627A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | WO2001026626A1 Flocculated suspension of megestrol acetate |
| 04/19/2001 | WO2001026625A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 04/19/2001 | WO2001026621A2 Orally distintegrating composition comprising mirtazapine |
| 04/19/2001 | WO2001003741B1 Growth hormone formulations |
| 04/19/2001 | WO2001003670A8 Method for controlled production of ultrafine microparticles and nanoparticles |
| 04/19/2001 | WO2001001963A8 A method for the improvement of transport across adaptable semi-permeable barriers |
| 04/19/2001 | WO2000061132A8 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 04/19/2001 | WO2000057873A3 Granulate with high content of l-carnitine or an alkanoyl l-carnitine |
| 04/19/2001 | WO2000047236A8 Matrices for drug delivery and methods for making and using the same |
| 04/19/2001 | DE19950017A1 Emulsifier mixture of high stability, useful in pharmaceutical and cosmetic compositions, prepared by reaction of fatty acid, sugar alcohol and glycerine carbonate |
| 04/19/2001 | DE19949897A1 Shaped article, e.g. in stick form, for controlled release of drugs in wounds or body cavities, comprising hydrophilic outer phase, lipophilic inner phase and drug, e.g. antibiotic |
| 04/19/2001 | DE19949518A1 Novel primary mono-fatty acid esters of glycerol self-condensation products, useful as surfactants in cosmetics, pharmaceuticals, foods, detergents or cleaning compositions, comprises specific structure |
| 04/19/2001 | DE19949284A1 Chirale Verbindung und deren Verwendung als chirale Dotierstoffe zur Herstellung von cholesterisch-flüssigkristallinen Zusammensetzungen Chiral compound and their use as chiral dopants for the production of cholesteric liquid crystal compositions |
| 04/19/2001 | DE19947559A1 Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung Antibody-dye conjugates against targets angiogenesis for intraoperative tumor boundary representation |
| 04/19/2001 | CA2389652A1 Archaeosomes as immunomodulating carriers for acellular vaccines to induce cytotoxic t lymphocyte(ctl) responses and protect the vaccinated host against intracellular pathogens and cancer |
| 04/19/2001 | CA2388991A1 Conjugates between a peptides and a nucleic acid analog, such as a pna, lna or a morpholino |
| 04/19/2001 | CA2388053A1 Cationic dosper virosomes |
| 04/19/2001 | CA2387621A1 Extended release formulations of erythromycin derivatives |
| 04/19/2001 | CA2387205A1 Interferon complex and pharmaceutical use thereof |
| 04/19/2001 | CA2387145A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | CA2386848A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 04/19/2001 | CA2386164A1 Neutral-cationic lipid for nucleic acid and drug delivery |
| 04/19/2001 | CA2385096A1 Estradiol conjugates and uses thereof |
| 04/19/2001 | CA2354558A1 Oral pharmaceutical composition |
| 04/18/2001 | EP1092728A2 Biologically digestable complex of orthosilicic acid in a solid, stable and concentrated form and proces for its preparation |
| 04/18/2001 | EP1092721A1 Chiral glucosides and their use as chiral dopants for the production of cholesteric liquid crystalline compositions |
| 04/18/2001 | EP1092434A1 Novel composition containing lansoprazole and process for its preparation |
| 04/18/2001 | EP1092433A2 Compositions and methods for treating or preventing inflammatory diseases |
| 04/18/2001 | EP1092430A1 Non-chlorofluorocarbon aerosol formulations |
| 04/18/2001 | EP1092429A1 Pharmaceutical preparations for drugs of low solubility |
| 04/18/2001 | EP1092428A1 Method for limiting the penetration in the skin or in keratin fibers of a cosmetic or pharmaceutical agent |
| 04/18/2001 | EP1092027A1 Therapeutic and diagnostic domain 1 beta 2 gp1 polypeptides and methods of using same |
| 04/18/2001 | EP1091761A1 Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
| 04/18/2001 | EP1091760A1 Pharmaceutical composition containing an ester or amide pla2 inhibitor |
| 04/18/2001 | EP1091757A2 Alpha emitting constructs and uses thereof |